ISRCTN72807124已完成3 期
A phase III randomised, double-blind trial of immunotherapy with a polyvalent melanoma vaccine (C-VAX) plus bacille Calmette-Guerin (BCG) versus placebo plus BCG as a post surgical treatment for stage IV melanoma
Department of Health (UK)0 个研究点目标入组 0 人开始时间: 2003年9月12日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with resected stage IV melanoma.
排除标准
- •Does not match inclusion criteria
研究者
相似试验
进行中（未招募）
1 期
A trial testing lenalidomide and dexamethasone after standard radiotherapy in patients with solitary bone plasmacytoma who are at a high risk of relapseEUCTR2015-001355-76-GBniversity College London140
招募中
3 期
Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAIRCT20210620051639N3Bagheiat-allah University of Medical Sciences10,300
已完成
1 期
Seasonal influenza vaccine study to determine the effect of an adjuvanted 2012 influenza vaccine in adultsPrevention of influenza infectionInfection - Other infectious diseasesPublic Health - Other public healthACTRN12612000709842Vaxine Pty Ltd200
进行中（未招募）
1 期
Immunogenicity, Tolerability, and Manufacturing Consistency study of a Multivalent HPV, VLP vaccinePrevention of cervical, vulvar, and vaginal cancers and related precancers, externalgenital lesions, Pap test abnormalities, and persistent infection caused by humanpapillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2009-011617-25-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,2,000
已完成
3 期
A Study of V503 (Multivalent HPV Vaccine) in Preadolescents and Adolescents. This study will evaluate the immunogenicity and tolerability of V503 in preadolescent and adolescent subjects between 9 and 15 years old and demonstrate the consistency of the manufactured vaccine through assessment of 3 different final manufacturing process lots of V503.CTRI/2009/091/000767Merck Sharp and Dohme2,800